Abstract
Fifty years ago, drug treatment of all forms of malaria was simple. Regardless of whether malaria was due to Plasmodium falciparum or Plasmodium vivax, chloroquine was the drug of choice, because it has the major advantages of being cheap, safe, and effective. Chloroquine was originally developed in a top secret US Army research project during World War II, with the military imperative to keep it out of the hands of Germans occupying North Africa. In the 1950s, in the context of a worldwide malaria eradication campaign, and because chloroquine was inexpensive to provide in malaria-endemic regions, chloroquine-resistant malaria began to emerge, first in southeast Asia and, independently, in South America [1]. Curiously, for several decades, all cases of chloroquine-resistant malaria were associated solely with P. falciparum. Chloroquine-resistant P. vivax was not reported until 1989, when it appeared in Papua, New Guinea [2], despite the long history of heavy global chloroquine use throughout the region where both P. falciparum and P. vivax were endemic.

This publication has 11 references indexed in Scilit: